Vonoprazan + Placebo
Phase 3Completed 0 views this week 0 watching💤 Quiet
Interest: 34/100
34
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Erosive Gastro-Esophageal Reflux Disease
Conditions
Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn
Trial Timeline
Jan 17, 2022 → May 17, 2023
NCT ID
NCT05195528About Vonoprazan + Placebo
Vonoprazan + Placebo is a phase 3 stage product being developed by Phathom Pharmaceuticals for Non-Erosive Gastro-Esophageal Reflux Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05195528. Target conditions include Non-Erosive Gastro-Esophageal Reflux Disease, Heartburn.
What happened to similar drugs?
0 of 4 similar drugs in Non-Erosive Gastro-Esophageal Reflux Disease were approved
Approved (0) Terminated (0) Active (4)
Hype Score Breakdown
Clinical
17
Activity
8
Company
9
Novelty
0
Community
0
Clinical Trials (3)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06851559 | Phase 2 | Recruiting |
| NCT05195528 | Phase 3 | Completed |
| NCT04799158 | Phase 2 | Completed |
Competing Products
6 competing products in Non-Erosive Gastro-Esophageal Reflux Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| YH1885L(Revaprazan) + Esomeprazole 20mg + placebo | Yuhan | Phase 2 | 35 |
| E3810 + E3810 + Placebo | Eisai | Phase 3 | 40 |
| RABEPRAZOLE SODIUM + RABEPRAZOLE SODIUM | Eisai | Phase 3 | 40 |
| Omeprazole | AstraZeneca | Phase 3 | 40 |
| Omeprazole | AstraZeneca | Phase 3 | 40 |
| Vonoprazan + Placebo | Phathom Pharmaceuticals | Phase 2 | 29 |